Market cap
$492 Mln
Revenue (TTM)
$37 Mln
P/E Ratio
--
P/B Ratio
108.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -78.00 | -67.33 | 16.14 | 45.25 | 53.39 |
| EBIT | -384.55 | -4.09 | 46.34 | 9.35 | -20.16 |
| Net Profit | -269.84 | 84.18 | 56.26 | 12.28 | -8.75 |
| EPS | -263.36 | 86.75 | 58.97 | 16.61 | 10.29 |
| Book Value | -- | -- | -90.97 | -65.28 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -333.97 | -519.83 | -102.25 | -214.08 | -493.58 |
| Net Margin
| -475.26 | -525.37 | -82.66 | -- | -704.22 |
| Return on equity
| -190.55 | -151.77 | -1,174.47 | -211.56 | -297.45 |
| Return on Capital
| -146.98 | -111.92 | -- | -146.49 | -241.89 |
| Return on Assets
| -62.34 | -52.99 | -30.37 | -58.59 | -101.78 |
| Debt to Equity (x)
| -- | -- | 0.00 | 2.96 | 0.21 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
--
|
-146.49
|
-241.89
|
-52.55
|
-186.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-1,174.47
Lower than Peers by 1,134.07
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
-1,174.47
|
-211.56
|
-297.45
|
-62.65
|
-255.25
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-30.37
Higher than Peers by 0.61
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
-30.37
|
-58.59
|
-101.78
|
-26.64
|
-37.25
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-102.25
Lower than Peers by 18.63
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
-102.25
|
-214.08
|
-493.58
|
-294.26
|
-1,007.55
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-82.66
Higher than Peers by 10.01
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
-82.66
|
-210.36
|
-704.22
|
-246.31
|
-615.19
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
16.14
Lower than Peers by 37.81
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
16.14
|
0.35
|
0.36
|
2.02
|
0.22
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
46.34
Higher than Peers by 47.14
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
46.34
|
41.48
|
-127.45
|
11.81
|
-107.80
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
56.26
Higher than Peers by 63.56
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
56.26
|
59.66
|
-258.87
|
10.81
|
-90.00
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
58.97
Higher than Peers by 44.32
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
58.97
|
0.61
|
-1.77
|
0.13
|
-0.85
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-77.51
Lower than Peers by 67.34
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
-77.51
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
--
|
2.96
|
0.21
|
0.25
|
0.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.65
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
0.65
|
0.45
|
0.03
|
0.02
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.89
Lower than Peers by 3.92
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
1.89
|
1.04
|
2.33
|
2.71
|
6.69
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.89
Lower than Peers by 3.80
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
1.89
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-6.46
Lower than Peers by 4.37
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
-6.46
|
-115.03
|
-3,891.70
|
--
|
--
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
--
|
--
|
3.64
|
--
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.37
Higher than Peers by 0.30
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
0.37
|
0.28
|
0.14
|
0.10
|
0.04
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
--
|
9.84
|
13.28
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
--
|
435.07
|
292.50
|
--
|
30.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
--
|
-0.04
|
-0.15
|
-0.90
|
-0.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
108.42
Higher than Peers by 103.24
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
108.42
|
0.45
|
0.43
|
0.78
|
0.39
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-18.71
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
-18.71
|
0.53
|
6.70
|
1.43
|
2.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
492
Higher than Peers by 346
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Harpoon Therapeutics (HARP)
|
492
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|